Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 8-K, filed Oct 20, 2026
- Incorporated
- Delaware
- Filings on record
- 232 filings
- On EDGAR
- CIK 2012593
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
Financials 8 of 9
News 8 of 22
Prospectuses and Registrations 8 of 12
- S-3ASR Automatic shelf registration Mar 10, 2026
- S-8 Registration statement for an employee plan Mar 10, 2026
- 424B5 Prospectus supplement for an offering Jan 7, 2026
- 424B5 Prospectus supplement for an offering Sep 10, 2025
- 424B5 Prospectus supplement for an offering Sep 8, 2025
- S-3 Shelf registration statement Jul 1, 2025
- S-3 Shelf registration statement Jul 1, 2025
- S-8 Registration statement for an employee plan Mar 11, 2025
Proxies 4
Ownership 8 of 161
- 4 Insider reported a trade Oct 8, 2026
- 144 Notice of a proposed sale of restricted stock Oct 6, 2026
- 4 Insider reported a trade Oct 1, 2026
- 144 Notice of a proposed sale of restricted stock Sep 30, 2026
- 4 Insider reported a trade Sep 24, 2026
- 4 Insider reported a trade Sep 9, 2026
- 4 Insider reported a trade Aug 26, 2026
- 4 Insider reported a trade Aug 26, 2026
Other 8 of 24
- ARS Annual report sent to shareholders Apr 23, 2026
- EFFECT Notice that a registration became effective Jul 9, 2025
- EFFECT Notice that a registration became effective Jul 9, 2025
- CORRESP Reply to SEC staff Jul 7, 2025
- CORRESP Reply to SEC staff Jul 7, 2025
- UPLOAD Comment letter from SEC staff Jul 7, 2025
- UPLOAD Comment letter from SEC staff Jul 7, 2025
- ARS Annual report sent to shareholders Apr 24, 2025
Everything here comes from Rapport Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.